PDF(Pubmed)
Abstract：
BACKGROUND: In Chinese healthcare settings, drug selection decisions are predominantly influenced by the Pharmacy & Therapeutics Committee (PTC). This study evaluates two recently introduced potassium-competitive acid blockers, vonoprazan (VPZ) and tegoprazan (TPZ), utilizing the Evidence and Value: Impact on DEcisionMaking (EVIDEM) framework.
METHODS: The study employed the 10th edition of EVIDEM, which includes a core model with five domains and 13 criteria. Two independent expert panels were involved: the PTC expert panel, tasked with assigning weights using a 5-point scale, defining scoring indicators, examining the evidence matrix, scoring, and decision-making; and the evidence matrix expert panel, responsible for conducting a systematic literature review, creating the evidence matrix, and evaluating the value contributions of VPZ and TPZ.
RESULTS: The analysis estimated the value contributions of VPZ and TPZ to be 0.59 and 0.54, respectively. The domain of \'economic consequences of intervention\' showed the most significant variation in value contribution between the two drugs, followed by \'comparative outcomes of intervention\' and \'type of benefit of intervention\'.
CONCLUSIONS: Employing the EVIDEM framework, VPZ\'s value contribution was found to be marginally superior to that of TPZ. The EVIDEM framework demonstrates potential for broader application in Chinese medical institutions.
METHODS: The study employed the 10th edition of EVIDEM, which includes a core model with five domains and 13 criteria. Two independent expert panels were involved: the PTC expert panel, tasked with assigning weights using a 5-point scale, defining scoring indicators, examining the evidence matrix, scoring, and decision-making; and the evidence matrix expert panel, responsible for conducting a systematic literature review, creating the evidence matrix, and evaluating the value contributions of VPZ and TPZ.
RESULTS: The analysis estimated the value contributions of VPZ and TPZ to be 0.59 and 0.54, respectively. The domain of \'economic consequences of intervention\' showed the most significant variation in value contribution between the two drugs, followed by \'comparative outcomes of intervention\' and \'type of benefit of intervention\'.
CONCLUSIONS: Employing the EVIDEM framework, VPZ\'s value contribution was found to be marginally superior to that of TPZ. The EVIDEM framework demonstrates potential for broader application in Chinese medical institutions.
摘要：
背景：在中国医疗机构中，药物选择决定主要受药学和治疗学委员会(PTC)的影响。这项研究评估了最近推出的两种钾竞争性酸阻滞剂，vonoprazan（VPZ）和tegoprazan（TPZ），利用证据和价值：对决策的影响(EVIDEM)框架。
方法：本研究采用EVIDEM第10版，其中包括一个具有五个域和13个标准的核心模型。两个独立的专家小组参与其中：PTC专家小组，任务是使用5点刻度分配权重，定义评分指标，检查证据矩阵，得分,和决策；以及证据矩阵专家小组，负责进行系统的文献综述，创建证据矩阵,并评估VPZ和TPZ的价值贡献。
结果：分析估计VPZ和TPZ的价值贡献分别为0.59和0.54。“干预的经济后果”领域显示了两种药物之间价值贡献的最显著差异，其次是“干预措施的比较结果”和“干预措施的获益类型”。
结论：采用EVIDEM框架，发现VPZ的价值贡献略高于TPZ。EVIDEM框架展示了在中国医疗机构中更广泛应用的潜力。
方法：本研究采用EVIDEM第10版，其中包括一个具有五个域和13个标准的核心模型。两个独立的专家小组参与其中：PTC专家小组，任务是使用5点刻度分配权重，定义评分指标，检查证据矩阵，得分,和决策；以及证据矩阵专家小组，负责进行系统的文献综述，创建证据矩阵,并评估VPZ和TPZ的价值贡献。
结果：分析估计VPZ和TPZ的价值贡献分别为0.59和0.54。“干预的经济后果”领域显示了两种药物之间价值贡献的最显著差异，其次是“干预措施的比较结果”和“干预措施的获益类型”。
结论：采用EVIDEM框架，发现VPZ的价值贡献略高于TPZ。EVIDEM框架展示了在中国医疗机构中更广泛应用的潜力。
